ArticleProceedings of the National Academy of Sciences of the United States of America2002
Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 109 citations in OpenAlex.
- Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms.Communications biology · 2023Article
- Review
- Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Somatic and germline genomics in paediatric acute lymphoblastic leukaemia.Nature reviews. Clinical oncology · 2019Review
- Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia.Nature communications · 2018Article
- Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells.The EMBO journal · 2018Article
- MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.Journal of cancer research and clinical oncology · 2018Article
- The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma.Oncogene · 2016Article
- The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.Gene expression · 2015Review
- Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo.Oncogenesis · 2013Article
- Antibody-based therapeutics for the treatment of human B cell malignancies.Current allergy and asthma reports · 2013Review
- Article
- Subcutaneous passage increases cell aggressiveness in a xenograft model of diffuse large B cell lymphoma.Clinical & experimental metastasis · 2012Article
- The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas.Advances in hematology · 2012Article
- The immunoglobulin heavy chain gene 3' enhancers induce Bcl2 deregulation and lymphomagenesis in murine B cells.Leukemia · 2011Article
- Regulation of cell differentiation by the DNA damage response.Trends in cell biology · 2011Review
- Molecular basis of CLL.Seminars in cancer biology · 2010Review
- Article
- The histopathologic and molecular basis for the diagnosis of histiocytic sarcoma and histiocyte-associated lymphoma of mice.Veterinary pathology · 2010Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
The TCL1 protooncogene is overexpressed in many mature B cell lymphomas, especially from AIDS patients. To determine whether aberrant expression promotes B cell transformation, we generated a murine model in which a TCL1 transgene was overexpressed at similar levels in both B and T cells. Strikingly, transgenic mice developed Burkitt-like lymphoma (BLL) and diffuse large B cell lymphoma (DLBCL) with attendant Bcl-6 expression and mutated J(H) gene segments at a very high penetrance beginning at 4 months of age. In contrast, only one mouse developed a T cell malignancy at 15 months, consistent with a longer latency for transformation of T cells by TCL1. Activation of premalignant splenic B cells by means of B cell antigen receptor (BCR) engagement resulted in significantly increased proliferation and augmented AKT-dependent signaling, including increased S6 ribosomal protein phosphorylation. Transgenic spleen cells also survived longer than wild-type spleen cells in long-term culture. Together these data demonstrate that TCL1 is a powerful oncogene that, when overexpressed in both B and T cells, predominantly yields mature B cell lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.